Raloxifene

Raloxifene is a SERM, a selective estrogen receptor modulator, but a very different one from tamoxifen. It blocks estrogen at the breast aggressively, which is why it outperforms tamoxifen for reversing established gynecomastia. It acts as a mild estrogen agonist at bone, which is its original clinical job: osteoporosis prevention in postmenopausal women. And it is far gentler on the uterus than tamoxifen, which carries an endometrial cancer signal, though an eight-year trial still found uterine polyps more common with raloxifene than placebo. Where it falls short for the PCT crowd is the hypothalamus: raloxifene is weaker at driving LH and FSH back up than tamoxifen, which makes it a poor standalone restart tool.

In practice, the community uses it for one purpose: a gyno lump that tamoxifen did not fully clear, or one caught late enough that you want the strongest local estrogen block available. Some people run it alongside tamoxifen during PCT, letting tamoxifen handle the axis restart while raloxifene targets the breast tissue. That combination makes sense mechanistically, though no trial has tested it in men coming off a cycle.

Raloxifene’s trial data is enormous, but almost entirely in postmenopausal women for osteoporosis and breast cancer prevention. The gyno-reversal use in men is pharmacological extrapolation from that breast-tissue potency, not a dedicated trial:

Raloxifene is a gyno tool, not a restart tool. If you need PCT, run tamoxifen. If you have a gyno lump that tamoxifen is not clearing, or if you want the strongest estrogen block at the breast, add raloxifene.

The standard community protocol for gyno reversal is 60 mg per day for three to six months. Some people start at 30 mg to test tolerance and step to 60 after a couple of weeks. Results are slow, the lump shrinks gradually, and stopping too early is the most common mistake. If three months at 60 mg has not moved it, it is probably fibrosed tissue that no SERM will dissolve, and that conversation becomes surgical.

If you are running it alongside tamoxifen for PCT, the tamoxifen handles the axis restart at its usual 20 mg while raloxifene runs at 60 mg for the chest. That stack doubles your SERM load, so keep the run as short as the gyno requires.

Stay hydrated, move around, and do not sit still for long flights or drives while on it. The clot risk is dose-and-time dependent, and basic circulation hygiene is the cheapest insurance.

The side profile is well mapped from massive trials in women. In men at gyno doses the picture is similar: